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CASE REPORT Open Access
A novel germline ARMC5 mutation in a
patient with bilateral macronodular adrenal
hyperplasia: a case report
Qiuli Liu1, Dali Tong1, Jing Xu1, Xingxia Yang1, Yuting Yi2, Dianzheng Zhang3, Luofu Wang1, Jun Zhang1,
Yao Zhang1, Yaoming Li1, Lianpeng Chang2, Rongrong Chen2, Yanfang Guan2, Xin Yi2 and Jun Jiang1*
Abstract
Background: Bilateral macronodular adrenal hyperplasia (BMAH) is a rare cause of Cushing’s syndrome (CS). BMAH is
predominantly believed to be caused by two mutations, a germline and somatic one, respectively, as described in the
two-hit hypothesis. In many familial cases of BMAH, mutations in armadillo repeat containing 5 (ARMC5), a putative
tumor suppressor gene, are thought to induce the disorder. The objective of this study was to report a case in which
the patient presented with BMAH induced by a novel heterozygous germline ARMC5 mutation (c. 517C > T, p. Arg173*)
alone rather than a two-hit mutation.
Case presentation: A 51-year-old woman was identified with masses in the bilateral adrenals. Serum cortisol levels
were increased significantly both in the morning (08:00 AM) and late at night (24:00 AM), while plasma
adrenocorticotropic hormone was normal. The patient underwent a left adrenalectomy and histopathology
substantiated the BMAH diagnosis. WES of the germline DNA discovered a novel heterozygous germline ARMC5
mutation (c. 517C > T, p. Arg173*) and in silico analysis predicted that the mutation significantly impaired protein
function, resulting in inactivated ARMC5. Subsequently, WES of the tumor specimen identified 79 somatic single
nucleotide polymorphisms (SNPs)/insertion-deletion (indel) mutations, including 32 missense/nonsense/splice/stop-loss
mutations. None of these mutations were CS-related.
Conclusions: A novel germline ARMC5 mutation (c. 517C > T, p. Arg173*) was identified that induced BMAH alone
without a second mutation. ARMC5 sequencing may improve the identification of clinical forms of BMAH and allow
earlier diagnosis of this disease.
Keywords: Bilateral macronodular adrenal hyperplasia, Cushing’s syndrome, ARMC5
Background
Bilateral macronodular adrenal hyperplasia (BMAH) is a
rare type of Cushing’s syndrome (CS) that accounts for
less than 1% of all endogenous CS cases [1]. BMAH is
characterized by bilateral enlargement of the adrenal
glands, with adrenocortical nodule diameters larger than
10 mm and frequently closer to 30 or 40 mm. Patients
with BMAH also present with abnormal cortisol produc-
tion and reduced expression of steroidogenic enzymes
and Melanocortin type 2 receptor (MC2R) [2]. Usually,
the disease progresses slowly, and patients are diagnosed
between 40 and 60 years old only after they present with
CS and suppressed circulating corticotropin levels [3].
One potential reason for the slow disease progression is
that increased overall cortisol production only occurs
when the patients have developed large adrenal nodules
[3]. Indeed, most BMAH patients are identified while
investigating for an incidentally discovered bilateral
adrenal lesion. Importantly, the bilateral appearance of
the nodules raised the hypothesis of an underlying germ-
line genetic predisposition. Although most cases appear
sporadic, familial cases are well documented, indicating
a potential major genetic component of the disease [4].
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Many familial cases of BMAH are associated with muta-
tions in ARMC5, a putative tumor suppressor gene, which
are thought to underlie this form of the disorder [3]. About
45–55% of BMAH cases are thought to be associated with
the variations in ARMC5 [3, 5]. These mutations inactivate
ARMC5 and slowly induce dedifferentiation of adrenocorti-
cal cells and growth of bilateral masses. ARMC5-mutant
patients also present with a more severe disease than wild-
type patients. Specifically, in the mutated group, the age of
diagnosis is lower, while the prevalence of clinical CS and
hypertension, the total adrenal weights, and the number of
nodules are all higher [4].
Inactivation of ARMC5 in BMAH follows the “two-hit”
model of a tumor suppressor gene responsible for a heredi-
tary neoplasia syndrome. BMAH patients have a single
germline mutation in ARMC5 leading to the expression of
an inactive mutant protein, acting as the first ‘hit’; however,
the other allele could encode for the protein. The BMAH
would happen only if the other allele suffered another sub-
sequent somatic mutation which resulted in the absence of
the protein and causing the development of nodules and
overproduction of cortisol [6]. Moreover, tumors caused by
mutations in ARMC5 are likely to be polyclonal, because
both alleles of ARMC5 carry mutations at both the somatic
and germline levels. Therefore, different nodules on the
same adrenal gland may carry different variations of the
ARMC5 gene [7]. In this study, we present a patient with
BMAH induced by a novel heterozygous germline ARMC5
mutation (c. 517C >T, p. Arg173*) alone rather than the
previously hypothesized two-hit somatic mutation.
Case presentation
A 51-year-old woman was admitted to our department
for 2 months to identify masses in the bilateral adrenals.
Physical examination revealed typical Cushingoid
features, including a full moon face, central obesity, and
purple striae of the bilateral axillary and lower abdomen.
Upon admission, the hormonal work-up revealed
hypercortisolism both in the morning and late at night.
Specifically, 8:00 morning serum cortisol levels were
604 nmol/L (normal range: 50-280 nmol/L) and 24:00
levels were 443 nmol/L (normal range: 10-120 nmol/L)
(Table 1). Plasma ACTH levels were normal at both time
points, at 11.72 pg/mL (normal range: 5.08-32.8 pg/mL)
and 12.27 pg/mL (normal range: 5-15 pg/mL), for morn-
ing and night levels, respectively. The results of low- and
high-dose dexamethasone suppression tests were nega-
tive, indicating the latter mentioned adrenal masses were
corticotropin independent. Levels of other hormone
were also abnormal, including Thyroxine (T4): 41.
83 nmol/L (normal range: 78.38-157.4 nmol/L) and free
T4: 5.16 pmol/L (normal range: 7.84-20.1 pmol/L), while
estradiol, testosterone, FSH (follicle-stimulating
hormone), LH (luteinizing hormone), growth hormone,
thyrotropin (TSH), and prolactin (PRL) levels were all
normal.
Adrenal computed tomography (CT) revealed bilateral
adrenal masses (left: 3.2*2.4 cm and right: 2.2*2.1 cm)
(Fig. 1a and b), while chest CT revealed an old right rib
fracture. Pituitary magnetic resonance imaging (MRI)
was normal, whereas vertebral MRI revealed a compres-
sion fracture of the thoracolumbar spine (T7 and L3).
On January 19th, 2016, the patient underwent a left
adrenalectomy using the retroperitoneal laparoscopic
procedure. Surgically removed adrenal glands demon-
strated nodular hyperplasia without hemorrhage or in-
farction, and histopathology substantiated the BMAH
diagnosis (Fig. 1c and d).
Precise isolation of the tumor specimen during the
sample collection was conducted with the help of the
Table 1 Patient hormone expression profile
Hormone (reference range) On first admission After left adrenalectomy On second admission
Cortisol 8, ng/mL (50–280 ng/mL) 604 244 217
Cortisol 16, ng/mL (20–140 ng/mL) 361 294 252
Cortisol 24, ng/mL (10–120 ng/mL) 443 273 281
ACTH 8, pg/mL (5.08–32.8 pg/mL) 11.72 7.21 7.06
ACTH 16, pg/mL (10.7–30.5 pg/mL) 9.25 9.17 10.44
ACTH 24, pg/mL (5–15 pg/mL) 12.27 9.25 5.25
Vanillylmandelic acid, μmol/24 h (9.6-50.0 μmol/24 h urine) 23.40 – 29.80
17-hydroxycorticosteroid, μmol/24 h (5.5-33.2 μmol/24 h urine) 14.30 – 15.80
17-ketosteroid, μmol/24 h (13.9-76.3 μmol/24 h urine) 43.90 – 52.70
Orthostatic renin activity, ng/mL/h (0.33-5.15 ng/mL/h) 5.96 – 9.19
Clinostatic renin activity, ng/mL/h (0.07-1.51 ng/mL/h) 2.25 – 15.88
Thyroxine, T4, nmol/L (78.38-157.4 nmol/L) 41.83 – –
Free thyroxine, nmol/L (7.86-20.1 nmol/L) 0.1 – –
Abbreviations: ACTH adrenocorticotropic hormone
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H&E staining. Using WES (whole-exome sequencing) of
the germline and tumor DNA, we first identified a novel
heterozygous germline ARMC5 mutation (c. 517C > T, p.
Arg173*, chr16: 31473284) that resulted in a premature
translational-termination codon. This nonsense muta-
tion would impair the function of ARMC5. The ARMC5
variants identified by WES were validated by Sanger se-
quencing of the germline DNA (Fig. 1e). We then per-
formed segregation analysis of the variants. All coding
exons of ARMC5 in the patient were sequenced, and
then this sequence was analyzed using Mutation Sur-
veyor version 2.51 (SoftGenetics LLC) with comparison
to the reference sequence in GenBank (http://www.ncbi.
nlm.nih.gov/genbank/) Subsequently, we conducted
WES of the tumor specimen compared to matched nor-
mal DNA and identified 79 somatic single nucleotide
polymorphisms (SNPs)/insertion-deletion (indel) muta-
tions, including 32 missense/nonsense/splice/stop-loss
mutations (Additional file 1: Table S1). Among these, In
silico analysis predicted no known CS-related mutations.
The CARE guidelines were followed when reporting
this case.
Discussion and conclusion
In this study, we reported a rare case of BMAH in which
the patient presented with the typical bilateral adrenal
macronodular hyperplasia, BMAH-associated CS, and
hypertension. In this unique case of BMAH, the sequen-
cing results identified a novel heterozygous germline
ARMC5 mutation (c. 517C > T, p. Arg173*).
As these adrenal nodules inefficiently produce cortisol,
a clinical syndrome only becomes apparent with large
nodules. Previous studies predicted that this form of
BMAH becomes clinically apparent only with a second
somatic mutation in addition to ARMC5, as described in
Knudson’s two-hit model [3]. In these cases, ARMC5
would bear a first germline mutation and a second som-
atic mutation within the adrenals, resulting in a loss of
protein function and subsequent tumor formation [8].
However, in this case, BMAH development did not seem
Fig. 1 Results of imaging, histopathology, and DNA sequencing. a and b Adrenal computed tomography scan revealed bilateral adrenal masses
(indicated by red arrows). c and d Hematoxylin and eosin staining of the adrenal tissue revealed nodular hyperplasia. e. Sequencing of DNA
extracted from peripheral leukocytes identified a novel heterozygous germline ARMC5 mutation, c. 517C > T, p. Arg173*. (indicated by red arrows)
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to require a second mutation. The patient presented
with only a heterozygous germline ARMC5 mutation (c.
517C > T, p. Arg173*), and no mutations of the other
allele or of CS-related genes in the bilateral adrenal
tissues. This single germline ARMC5 mutation is not
entirely surprising, as Zilbermint et al. previously re-
ported a heterozygous germline ARMC5 mutation with
no additional somatic inactivating events in ARMC5
exons, such as loss of heterozygosity [7]. This cast doubt
on the pathogenic role of heterozygous ARMC5 muta-
tions in primary aldosteronism. Our results suggest that
ARMC5-induced BMAH does not require additional
somatic mutations, which was consistent with the
haploinsufficient model [9]. The combination of high-
frequency LOH and rare point mutations has led to the
suggestion that ARMC5 might demonstrate haploinsuffi-
ciency (absent or reduced function due to the loss or
inactivation of a single allele), just as CDKN1B described
by A. J. W. Paige [9]. However, this needs to be further
substantiated. Of course, similar to Correa et al. [10], we
cannot not exclude the possibility that other larger
genomic losses or the changes of the methylation, as
well as structural alterations including inversions and
copy number changes might exist that were not detected
by the methods used in this study.
BMAH is a heterogeneous disease with varying de-
grees of hypercortisolism (from subclinical to overt CS),
radiological aspects (from massive nodular hyperplasia
to macronodular adrenal hyperplasia), and illegitimate
receptors [11]. The presence or absence of ARMC5 mu-
tations may be associated with these diverse phenotypes.
Previous studies have shown that ARMC5 defects are as-
sociated with a more severe disease, such as higher cor-
tisol levels, larger adrenal glands and higher numbers of
nodules [3, 5]. In addition, ARMC5-mutated patients
have hypertension more often than WT (wild type) pa-
tients [12]. However, one important consideration is that
even if there is a connection between BMAH and ARMC5
mutations, the resulting phenotypes would vary with the
nature of the mutations. For example, Elbelt el al. [13]
reported that somatic (p.R502fs) and germline frame shift
ARMC5 mutations (c.323_324insC, p.A110fs*9) are asso-
ciated with intracranial meningioma, while other family
members lacking the somatic mutation did not develop
the disease. This indicates that specific ARMC5 mutations
are associated with unique disease phenotypes. In the
current study, the heterozygous germline ARMC5 muta-
tion (c. 517C > T, p. Arg173*) alone was potentially associ-
ated with younger age at diagnosis, BMAH, CS, and
hypertension.
In conclusion, we have identified a novel germline
ARMC5 mutation (c. 517C > T, p. Arg173*) in a sporadic
case of BMAH characterized with bilateral adrenal
macronodular hyperplasia, BMAH-associated CS, and
hypertension. Identification of this genotype-phenotype
relationship increases our knowledge regarding the
development of BMAH and the connection to ARMC5.
Determining patient ARMC5 status might enhance
BMAH diagnosis, and screening family members for
ARMC5 mutations may enable clinicians to identify
BMAH earlier and prevent patient morbidity and
mortality.
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